Menopause and Epilepsy

How perimenopause, menopause symptoms, hormone therapy, antiseizure medicines and long-term bone health can interact

Menopause is not a single day. It is a transition that includes perimenopause — the years when ovarian hormone production becomes more variable — followed by menopause and postmenopause.

For people with epilepsy, this transition can matter because fluctuating oestrogen and progesterone may alter seizure susceptibility, menopause symptoms can affect sleep and wellbeing, and hormone replacement therapy (HRT) can interact with some antiseizure medicines.

Research remains limited. Some people notice clear seizure changes around menopause; others do not.

Perimenopause can be less predictable than the years before it

During perimenopause, ovulation becomes less regular and hormone concentrations can fluctuate considerably from cycle to cycle.

For someone who previously had a predictable menstrual-related seizure pattern, this can make seizure timing less regular.

Some people with a history of Catamenial Epilepsy report increased seizure activity during perimenopause and improvement after menopause, but this is not universal.

Does menopause usually worsen epilepsy?

No single pattern applies to everyone.

Older clinical studies found that some women reported worsening, some improvement and some no change at all during the menopause transition.

A 2026 review similarly emphasises that the evidence remains sparse and that menopause does not produce a predictable seizure effect across all people with epilepsy.

This is why a new change in seizure frequency during midlife should not automatically be blamed on hormones without considering medication, sleep, illness, stress and other neurological causes.

Why hormones might affect seizure susceptibility

Oestrogen and progesterone influence brain excitability through several mechanisms.

Progesterone-derived neurosteroids generally enhance inhibitory GABA-related signalling, while oestrogen can have more complex and sometimes pro-excitatory effects.

During perimenopause, both hormones fluctuate irregularly. After menopause, ovarian production of both falls substantially.

The net seizure effect therefore depends on the individual rather than on a simple “more oestrogen equals more seizures” rule.

Menopause symptoms can affect epilepsy indirectly

Even when hormonal change does not directly alter seizure threshold, menopause symptoms can affect seizure control indirectly.

Examples include:

insomnia and fragmented sleep;
night sweats and hot flushes;
mood change and anxiety;
fatigue;
changes in alcohol use or caffeine intake;
missed medication because routines are disrupted.

For someone whose seizures are sensitive to sleep deprivation, severe vasomotor symptoms can therefore become clinically important even if the hormones themselves are not the main seizure trigger.

HRT is not automatically contraindicated in epilepsy

Having epilepsy does not automatically mean a person cannot use HRT.

NICE recommends HRT as an effective treatment for menopausal vasomotor symptoms in the general population, while epilepsy-specific guidance stresses that treatment needs to account for antiseizure medication interactions and seizure history.

The evidence on whether HRT changes seizure frequency in people with epilepsy is limited and conflicting.

What does the evidence say about HRT and seizures?

A 2023 systematic review found only three human studies examining HRT and seizure frequency in women with epilepsy.

Results were inconsistent: one study suggested lower seizure frequency, another suggested higher frequency, and a randomised trial found a dose-related increase in seizures with one older combined HRT regimen in women with focal epilepsy.

The review concluded that the evidence was too limited to define the seizure effect of HRT confidently.

That means HRT should not be described as universally safe for seizures, but neither should it be automatically withheld solely because somebody has epilepsy.

Modern HRT is not the same as older HRT studies

Much of the historical seizure concern comes from studies using older oral hormone preparations, including conjugated equine oestrogens combined with medroxyprogesterone acetate.

Modern menopause practice often uses different preparations, doses and routes, including transdermal oestradiol and micronised progesterone.

There are still not enough epilepsy-specific trials to say that one modern regimen is definitively best for seizure control.

Choice therefore needs to be individualised with the menopause prescriber and epilepsy team.

Lamotrigine is a particularly important interaction

NICE specifically warns that oestrogen-containing HRT can impair the effectiveness of lamotrigine.

Oestrogen can increase glucuronidation of lamotrigine, lowering its blood concentration. In someone whose seizures are well controlled on lamotrigine, starting HRT can therefore potentially reduce seizure protection.

If oestrogen-containing HRT is stopped, lamotrigine levels may rise again, increasing the risk of adverse effects if the dose has been increased meanwhile.

This is why HRT should not be started, stopped or substantially changed without informing the clinician managing the lamotrigine.

Should lamotrigine levels be monitored?

There is no universal rule that every person needs routine blood-level testing when starting HRT.

However, when seizure control is sensitive to lamotrigine concentration, baseline and follow-up levels can sometimes help guide dose adjustment alongside clinical symptoms.

The decision depends on previous seizure control, current dose, comorbidities and local specialist practice.

Other antiseizure medicines can interact with HRT

Some enzyme-inducing antiseizure medicines increase the metabolism of sex hormones and may reduce exposure to certain oral hormone preparations.

Examples include carbamazepine, phenytoin, phenobarbital and primidone.

The clinical significance depends on the HRT formulation and route.

Medication-specific advice is therefore preferable to treating all antiseizure medicines as though they interact in the same way.

Transdermal HRT

Transdermal oestrogen is often used in menopause care because it avoids first-pass liver metabolism and has a different thrombotic-risk profile from oral oestrogen.

However, transdermal delivery does not remove the possibility of interaction with lamotrigine because systemic oestrogen exposure can still affect lamotrigine metabolism.

The route of HRT therefore changes some risks, but does not make the epilepsy interaction disappear.

Progesterone and progestogens are not interchangeable

Natural micronised progesterone and synthetic progestogens are not pharmacologically identical.

Progesterone-derived neurosteroids have anticonvulsant effects in experimental models, but this does not mean that all progesterone-containing HRT will reliably improve seizures.

Clinical evidence in menopause remains too limited for HRT to be chosen primarily as an epilepsy treatment.

Non-hormonal treatment for menopause symptoms

Not everyone wants or can use HRT.

NICE recommends menopause-specific cognitive behavioural therapy as an option for vasomotor symptoms, either alongside HRT or when HRT is unsuitable or not wanted.

Other non-hormonal treatments can also be considered in menopause care, but the choice should take account of seizure threshold, sedation, interactions and the person’s existing medicines.

Non-hormonal does not automatically mean interaction-free.

Sleep can be a major part of the problem

Hot flushes, night sweats and insomnia can fragment sleep repeatedly.

For somebody whose epilepsy is sleep-sensitive, this may worsen seizure control even if hormone concentrations themselves are not directly responsible.

Treating sleep disruption can therefore be part of epilepsy management during menopause.

Mood, cognition and epilepsy

Menopause can be associated with changes in mood, attention, memory and subjective cognitive function.

Epilepsy and antiseizure medicines can also affect these same areas.

This overlap can make attribution difficult.

A new memory complaint should not automatically be labelled as menopause, epilepsy or medication without considering all three and screening for other causes such as depression, sleep disturbance, thyroid disease, anaemia or neurodegenerative illness when clinically appropriate.

Bone health becomes increasingly important

Bone density naturally declines after menopause because oestrogen levels fall.

Some antiseizure medicines are also associated with reduced bone mineral density and fracture risk, especially after long-term use.

The combination makes bone health particularly important in postmenopausal people with epilepsy.

Risk assessment can include diet, vitamin D, calcium intake, exercise, smoking, alcohol, falls, previous fractures and the specific antiseizure medicine being used.

Which antiseizure medicines are most relevant to bone health?

Older enzyme-inducing medicines such as phenytoin, carbamazepine and phenobarbital have long been associated with adverse effects on vitamin D metabolism and bone health.

Valproate has also been associated with reduced bone density through different mechanisms.

The evidence for newer medicines is more variable and in some cases still incomplete.

Long-term therapy should therefore be reviewed in the context of the person’s overall fracture risk rather than assuming all antiseizure medicines carry the same risk.

Falls matter more after menopause

Fracture risk is determined by both bone strength and fall risk.

People with seizures involving falls or loss of consciousness may have an additional injury risk, especially if osteoporosis is also present.

This makes seizure control, bone health and falls prevention interconnected issues rather than separate problems.

New seizures around menopause should still be investigated properly

A first seizure in midlife should not be assumed to be caused by menopause.

New-onset seizures require the same neurological assessment as at any other age, including consideration of structural, vascular, metabolic, immune, medication-related and other causes.

Hormonal change may influence seizure threshold, but it does not replace a diagnostic work-up.

Catamenial epilepsy may change after menopause

Someone who previously had a strong menstrual-linked pattern may find that the pattern changes during perimenopause and becomes less relevant after menstrual cycles stop.

Some older studies suggested that people with catamenial epilepsy were more likely to worsen during perimenopause and improve after menopause, but the evidence is limited.

Any cycle-specific treatment strategy therefore needs reviewing as menstruation becomes irregular and eventually ceases.

Do antiseizure medicines need changing just because menopause starts?

No.

Menopause alone is not a reason to switch an effective antiseizure medicine.

A medication review may still be useful if there are new interactions with HRT, worsening bone-health concerns, adverse effects, or a major change in seizure pattern.

Changes should be based on the whole clinical picture rather than the menopause label itself.

What should be discussed at review?

A menopause-and-epilepsy review can include:

whether seizure frequency or type has changed;
sleep and vasomotor symptoms;
current antiseizure medicines and interactions;
whether HRT is being considered or already used;
lamotrigine monitoring where relevant;
mood and cognition;
bone-health and fracture risk;
falls and injury risk;
other new neurological symptoms.

NICE specifically recommends that information about menopause is reviewed regularly as part of epilepsy care for women and girls across the lifespan.

The evidence gap

Menopause is a major life stage, but epilepsy-specific evidence remains surprisingly thin.

The 2023 systematic review of HRT found only three human studies, and a 2026 review again highlighted the shortage of evidence guiding menopause management in people with epilepsy.

This means clinicians often have to combine general menopause guidance, known drug interactions, limited epilepsy-specific studies and individual seizure history.

The key distinction

Menopause can modify epilepsy without necessarily causing it.

Hormonal fluctuations may alter seizure susceptibility, menopause symptoms may worsen sleep and indirectly affect seizures, HRT can interact with antiseizure medicines, and postmenopausal bone loss can compound medication-related fracture risk.

But there is no universal menopause seizure pattern and no reason to assume that every seizure change in midlife is hormonal.

The safest approach is to treat menopause and epilepsy as two interacting clinical issues that need coordinated review.

Sources and further reading

Evidence checked: September 2026.

This page is for general education and does not replace individual advice from an epilepsy specialist, GP, pharmacist or menopause clinician.